Compare · ABT vs AKTS
ABT vs AKTS
Side-by-side comparison of Abbott Laboratories (ABT) and Aktis Oncology Inc. (AKTS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and AKTS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 203.4x AKTS ($890.5M).
- Over the past year, ABT is down 18.4% and AKTS is down 31.9% - ABT leads by 13.5 points.
- ABT has been more active in the news (13 items in the past 4 weeks vs 2 for AKTS).
- ABT has more recent analyst coverage (25 ratings vs 14 for AKTS).
- Company
- Abbott Laboratories
- Aktis Oncology Inc.
- Price
- -
- -
- Market cap
- $181.14B
- $890.5M
- 1M return
- +2.58%
- -34.07%
- 1Y return
- -18.39%
- -31.86%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 13
- 2
- Recent ratings
- 25
- 14
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Aktis Oncology Inc.
Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., develops, designs, manufactures, and sells radio frequency (RF) filter products for the mobile wireless device industry in the United States. It operates through two segments, Foundry Fabrication Services and RF Filters. The Foundry Fabrication Services segment provides engineering review services; and semiconductor wafer-manufacturing and microelectromechanical systems foundry services. The RF Filters segment consists of amplifier and filter products. It offers RF filters for mobile wireless devices, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, military and defense applications. The company was incorporated in 2013 and is headquartered in Huntersville, North Carolina.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest AKTS
- Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3
- Chief Medical Officer Czibere Akos exercised 12,500 shares at a strike of $4.95 and sold $258,621 worth of shares (12,500 units at $20.69) as part of a pre-agreed trading plan (SEC Form 4)
- Oppenheimer initiated coverage on Aktis Oncology with a new price target
- Aktis Oncology to Present at Upcoming September Investor Conferences
- Wedbush initiated coverage on Aktis Oncology with a new price target
- BMO Capital Markets initiated coverage on Aktis Oncology with a new price target
- SEC Form 10-Q filed by Aktis Oncology Inc.
- Aktis Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Aktis Oncology Reports Financial Results and Business Highlights for the Second Quarter 2026
- Director Herrmann Ken exercised 4,856 shares at a strike of $0.59 and sold $119,274 worth of shares (4,856 units at $24.56) (SEC Form 4)